Sunday, November 16, 2014

Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib.

This study found that tumor progression in patients with non-small cell lung cancer was associated with a significant worsening in health related quality of life. The findings confirm the value of progression-free survival as a patient-relevant end point.  (BMJ Open. 2014 Oct 31;4(10):e005762)
Read More